An FDA panel has voted against recommending approval of a booster COVID-19 shot for the general population – disappointing some public health officials.
The UK has outlined plans to top the immunity of the most vulnerable ahead of the winter.
You’ll read lots of different figures on this — six months, eight months, more — and that’s because the research is ongoing. We don’t yet have a concrete answer.
As we continue to roll out COVID-19 vaccines around the world, we’re learning people who are immunocompromised aren’t necessarily protected as well from the first two doses.
A 2015 paper on chicken virus evolution is being taken out of context and used to fuel fears about COVID-19 vaccines. Its lead author aims to clarify the science in hopes of saving lives.
People with weakened immune systems are at a high risk of severe and prolonged COVID-19 infections. An extra vaccine dose can bolster protection.
Getting first doses to countries short of supplies should be the priority, argues the World Health Organization.
If immunity is waning or ineffectual against new variants, then boosters could be needed – but there needs to be evidence that they’re necessary.
Weeks do matter when it comes to the Delta strain. With Australia still heavily reliant on the AstraZeneca vaccine, for now it makes sense to reduce the time between the first and second jab.
Though currently approved COVID-19 vaccines effectively provide immunity against the virus, it’s unclear how long that protection will last.
A public health expert outlines what Britons can expect from their upcoming booster programme.
Vaccination rates for COVID-19 have been lower than desired for herd immunity, or when enough people become immune for new infections to stop. What will life look like without it?
An immunologist explains that you get some protection from the first dose of the mRNA vaccines but you need two to build up strong immunity, particularly to newer coronavirus variants.